My Top 3 Dividend Kings to Buy for March 2026

AbbVie: pipeline depth (90 drug/device candidates) and strong product momentum (Skyrizi $5.0B in Q4, +32% YoY; Rinvoq $2.37B in quarter, +29.5%; Botox $3.76B in 2025) support a 54-year dividend increase streak and a 3.0% yield. Walmart: reported $713B in sales for 2025, U.S. e-commerce +27% in Q1 FY2026, shares up ~46% over 12 months and a 53-year dividend streak with a 0.8% yield. Consolidated Edison: 2025 net income $2.02B and EPS $5.66 vs $1.82B/$5.26 in 2024, planned capex ~$6.6B this year and $6.8B next, 52-year dividend streak and a 3.1% yield—utility cash flows underpin dividend reliability.

Analysis

AbbVie's public narrative is pipeline diversification; the less-discussed lever is capital allocation — management can choose to defend payout via M&A or buybacks if organic launches underperform. That creates a timing mismatch: clinical readouts are binary over 6–24 months while balance-sheet moves (debt-funded buybacks, asset sales) can be executed in weeks and amplify volatility. Also watch the CMO/supply chain footprint — successful ramp of specialty injectables strains contract manufacturers and can create margin compression even as top-line grows.

Walmart's e‑commerce traction masks margin decomposition and inventory velocity gains that are iterative rather than instantaneous; logistics capex yields unit-cost improvements but with lumpy near-term SG&A pressure. The more structural call option is on private‑label penetration and supplier re‑pricing power — those are multi-quarter plays that can expand gross margins without top-line growth. A direct counterparty is Amazon: AWS makes AMZN a different bet (profit engine) and thus a poor pure retail comp — use that to isolate pure retail economics.

Regulated utilities like ConEd embed rate-case optionality: approved recoverable capex can mechanically lift regulated returns but execution and regulator pushback are underappreciated tail risks. Rising long-term rates increase carrying costs for capex-heavy plans and compress utility equity returns if regulators do not adjust ROEs swiftly. Second‑order winners include transformer/manufacturing suppliers and grid‑automation vendors; failures hit credit metrics and equity multiples more than headline dividend narratives suggest.

Key Decisions for Investors

• ABBV — Tactical directional: Buy a 12–18 month call-debit spread (buy 18‑month 25–30% OTM calls, sell 12‑month 60% OTM calls) sized ~2% NAV to capture upside from multiple phase‑3 readouts while capping premium paid. Hedge: purchase 9–12 month 20% OTM puts sized to 50% of the notional long if the position is >1% NAV. R/R: asymmetric upside on successful readouts (2–4x) vs capped premium loss on failure.
• WMT / AMZN — Relative-value pair: Go long WMT equity funded by short AMZN equity sized dollar-neutral (~3% NAV each leg) for a 3–9 month horizon to isolate core retail margin reversion. Exit/stop: unwind if AMZN outperforms WMT by >10% in 30 days or if WMT inventory days rise >10% QoQ. R/R: target 15–25% relative outperformance; tail risk is AMZN AWS re-rating.
• ED — Regulated-growth trade: Initiate long ED (2–3% NAV) vs underweight/short AWR (American Water Works) for 12–24 months to play faster rate-base growth in electric transmission vs water capex monetization. Use 10–15% position-level stops tied to adverse regulatory rulings. R/R: 20–30% total return if rate cases and capex recovery proceed; downside is regulatory disallowance compressing multiples.
• Income overlay — Option-enhanced yield on WMT: Sell covered calls (1–3 month expiries, 10–15% OTM) on an existing WMT position to harvest premium ahead of seasonal sales cycles. Expect incremental yield of 3–6% per quarter but cap upside; unwind if implied vols spike >40% or if open interest signals large directional flows.